News | September 20, 2024
Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL
Stable profits, low leverage to keep credit profiles comfortable
Stable profits, low leverage to keep credit profiles comfortable
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Subscribe To Our Newsletter & Stay Updated
